9:31 AM
 | 
May 04, 2018
 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

How AD vaccine UB-311 could be safer than other anti-beta amyloid therapies

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding the adverse events associated with prior AD vaccines and mAbs against the same target.

The first clinically tested AD vaccine, AN-1792 from Elan Corp. plc and Wyeth (now part of Pfizer Inc.), was able to activate natural antibody production against beta amyloid, but simultaneously triggered inflammatory T cell responses. The program was discontinued in 2002 after 6% of patients in a Phase II study of AN-1792 developed meningoencephalitis.

CMO Ajay Verma said United Neuroscience’s synthetic peptide vaccines derived from its UBITh platform are able to induce natural B cell-specific antibody responses while avoiding T cell inflammation. Inducing such an immune response could help the body naturally decrease beta amyloid levels to prevent further synaptic and neuronal...

Read the full 732 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >